Skip to main content
Erschienen in: Die Urologie 3/2009

01.03.2009 | Leitthema

Kombinationstherapie bei LUTS: Wann Pillen und wann nicht?

verfasst von: Prof. Dr. K. Höfner, M. Oelke

Erschienen in: Die Urologie | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf der Suche nach Optimierung der medikamentösen Therapie des BPS werden zunehmend Kombinationen von α1-Blockern mit 5α-Reduktasehemmern (5ARI), α1-Blockern mit Muskarinrezeptorantagonisten und α1-Blockern mit Phosphodiesterase-5- (PDE-5-)Hemmern getestet. Die umfangreichsten Daten sind für die Kombination von α1-Blockern mit 5ARI publiziert worden. Eine Kombinationsbehandlung mit einem α1-Blocker und 5α-Reduktasehemmer ist zur alleinigen Symptomreduktion nicht indiziert, allerdings zur Progressionshemmung des BPS geeignet und hierbei der Monotherapie überlegen. Die routinemäßige Kombinationstherapie aus α1-Blocker und Muskarinrezeptorantagonisten zur Behandlung der Symptome des BPS kann zurzeit aufgrund der unzureichenden Datenlage nicht empfohlen werden, auch wenn erste viel versprechende Ergebnisse vorliegen. Für die Kombinationstherapie aus α1-Blockern und Phosphodiesterase-5-Hemmern existieren nur erste vorläufige Daten, die überzeugende Vorteile gegenüber anderen Kombinationen bisher nicht erkennen lassen.
Literatur
1.
Zurück zum Zitat Abrams P (2003) Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 62: 28–40PubMedCrossRef Abrams P (2003) Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 62: 28–40PubMedCrossRef
2.
Zurück zum Zitat Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004PubMedCrossRef Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004PubMedCrossRef
3.
Zurück zum Zitat Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50–58PubMedCrossRef Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50–58PubMedCrossRef
4.
Zurück zum Zitat Athanasopoulos A, Gyftopoulos K, Giannitsas K et al (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169: 2253–2256PubMedCrossRef Athanasopoulos A, Gyftopoulos K, Giannitsas K et al (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169: 2253–2256PubMedCrossRef
5.
Zurück zum Zitat Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC (2001) Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58: 203–209PubMedCrossRef Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC (2001) Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58: 203–209PubMedCrossRef
6.
Zurück zum Zitat Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461–466PubMedCrossRef Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461–466PubMedCrossRef
7.
Zurück zum Zitat Debruyne FM, Jardin A, Colloi D et al (1998) Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group Eur Urol 34: 169–175 Debruyne FM, Jardin A, Colloi D et al (1998) Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group Eur Urol 34: 169–175
8.
Zurück zum Zitat Donovan JL, Abrams P, Peters TJ et al (1996) The ICS-’BPH‘ Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 77: 554–562PubMed Donovan JL, Abrams P, Peters TJ et al (1996) The ICS-’BPH‘ Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 77: 554–562PubMed
9.
10.
Zurück zum Zitat Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717–1723PubMedCrossRef Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717–1723PubMedCrossRef
11.
Zurück zum Zitat Kaplan SA, McConnell JD, Roehrborn CG et al (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175: 217–220PubMedCrossRef Kaplan SA, McConnell JD, Roehrborn CG et al (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175: 217–220PubMedCrossRef
12.
Zurück zum Zitat Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319–2328PubMedCrossRef Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319–2328PubMedCrossRef
13.
Zurück zum Zitat Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61: 119–126 Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61: 119–126
14.
Zurück zum Zitat Lee KS, Choo MS, Kim DY et al (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334–1338PubMedCrossRef Lee KS, Choo MS, Kim DY et al (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334–1338PubMedCrossRef
15.
Zurück zum Zitat Lepor H, Williford WO, Barry MJ et al (1996) The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 335: 533–539PubMedCrossRef Lepor H, Williford WO, Barry MJ et al (1996) The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 335: 533–539PubMedCrossRef
16.
Zurück zum Zitat McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398PubMedCrossRef McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398PubMedCrossRef
17.
Zurück zum Zitat McVary KT, Monnig W, Camps JL Jr (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071–1077PubMedCrossRef McVary KT, Monnig W, Camps JL Jr (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071–1077PubMedCrossRef
18.
Zurück zum Zitat Oelke M, Baard J, Wijkstra H et al (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54: 419–426PubMedCrossRef Oelke M, Baard J, Wijkstra H et al (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54: 419–426PubMedCrossRef
19.
Zurück zum Zitat Peters TJ, Donovan JL, Kay HE et al (1997) The international continence society „Benign Prostatic Hyperplasia“ Study: the botherosomeness of urinary symptoms. J Urol 157: 885–889PubMedCrossRef Peters TJ, Donovan JL, Kay HE et al (1997) The international continence society „Benign Prostatic Hyperplasia“ Study: the botherosomeness of urinary symptoms. J Urol 157: 885–889PubMedCrossRef
20.
Zurück zum Zitat Roehrborn CG (2006) Definition of at-risk patients: baseline variables. BJU Int 97(Suppl 2): 7–12PubMedCrossRef Roehrborn CG (2006) Definition of at-risk patients: baseline variables. BJU Int 97(Suppl 2): 7–12PubMedCrossRef
21.
Zurück zum Zitat Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT and ALF-ONE. BJU Int 101(Suppl 3): 17–21PubMedCrossRef Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT and ALF-ONE. BJU Int 101(Suppl 3): 17–21PubMedCrossRef
22.
Zurück zum Zitat Roehrborn CG, Kaplan SA, Jones JS et al (2008) Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: Effects of prostate size Eur Urol (Epub ahead of print) Roehrborn CG, Kaplan SA, Jones JS et al (2008) Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: Effects of prostate size Eur Urol (Epub ahead of print)
23.
Zurück zum Zitat Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228–1234PubMedCrossRef Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228–1234PubMedCrossRef
24.
Zurück zum Zitat Roehrborn CG, Siami P, Barkin J et al (2008) The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. Eur Urol (Epub ahead of print) Roehrborn CG, Siami P, Barkin J et al (2008) The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. Eur Urol (Epub ahead of print)
25.
Zurück zum Zitat Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179: 616–621PubMedCrossRef Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179: 616–621PubMedCrossRef
26.
Zurück zum Zitat Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47: 824–837PubMedCrossRef Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47: 824–837PubMedCrossRef
27.
Zurück zum Zitat Stief CG, Porst H, Neuser D et al (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236–1244PubMedCrossRef Stief CG, Porst H, Neuser D et al (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236–1244PubMedCrossRef
28.
Zurück zum Zitat Sullivan MP, Yalla SV (1996) Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol 155: 1995–2000PubMedCrossRef Sullivan MP, Yalla SV (1996) Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol 155: 1995–2000PubMedCrossRef
29.
Zurück zum Zitat Ückert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484–2490PubMedCrossRef Ückert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484–2490PubMedCrossRef
Metadaten
Titel
Kombinationstherapie bei LUTS: Wann Pillen und wann nicht?
verfasst von
Prof. Dr. K. Höfner
M. Oelke
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 3/2009
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-008-1919-7

Weitere Artikel der Ausgabe 3/2009

Die Urologie 3/2009 Zur Ausgabe

Berufspolitik BDU

Berufspolitik BDU

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.